Reminder: Roche’s Virtual Hematology Investor Event Dienstag, 11. Juni 2024 - 10:02

We are pleased to invite investors and analysts to participate in our virtual event on Sunday, 16 June 2024, to discuss Ph III STARGLO results in 2L+ DLBCL presented during the EHA congress and provide an update in non-malignant hematology.

13:00 – 14:00 CEST / 12:00 – 13:00 BST

07:00 – 08:00 am EDT / 04:00 – 05:00 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 12:00 CEST on the day of the event. > click here

Agenda
Introduction

Bruno Eschli, Head of Investor Relations

STARGLO: Columvi-GemOx for R/R DLBCL - Results of a Global Randomized Ph III Trial

Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Roche Bispecific Antibodies in NHL

William Waas, Lifecycle Leader NHL Bispecific Program, Global Product Strategy

Hemlibra: Improving Patient Experience

Daud Chaudry, Lifecycle Leader Hemlibra Program, Global Product Strategy

Q&A

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Rishard Salie

Investor Relations Officer

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com